Aquestive Therapeutics (AQST) Cash from Investing Activities (2017 - 2026)
Aquestive Therapeutics' (AQST) quarterly Cash from Investing Activities came in at -$52000.0 in Q1 2026, up 61.48% year-on-year from -$32201.8 in Q1 2025, and up 38.82% quarter-over-quarter from -$85000.0 in Q4 2025.
Aquestive Therapeutics (AQST) Cash from Investing Activities (2017 - 2026) Analysis & Trends
Aquestive Therapeutics' Cash from Investing Activities history runs 10 years deep, the most recent figure standing at -$52000.0 for Q1 2026.
- On a quarterly basis, Cash from Investing Activities rose 61.48% year-over-year to -$52000.0 in Q1 2026; TTM through Mar 2026 was -$479000.0, a 80.75% decrease from a year earlier, with the FY2025 full-year figure at -$562000.0, down 253.46% from the prior year.
- Cash from Investing Activities advanced to -$52000.0 in Q1 2026 per AQST's latest filing, from -$85000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$2000.0 in Q1 2023 and bottomed at -$1.7 million in Q3 2022.
- The 5-year median for Cash from Investing Activities is -$85000.0 (2025), against an average of -$252470.6.
- Across the five-year window, Cash from Investing Activities tumbled 1968.67% in 2022 and surged 98.08% in 2023, its largest moves.
- Year by year, Cash from Investing Activities stood at -$26000.0 in 2022, then soared by 38.46% to -$16000.0 in 2023, then climbed by 6.25% to -$15000.0 in 2024, then tumbled by 466.67% to -$85000.0 in 2025, then jumped by 38.82% to -$52000.0 in 2026.
- Per Business Quant, the three latest AQST Cash from Investing Activities figures stand at -$52000.0 (Q1 2026), -$85000.0 (Q4 2025), and -$235000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Aquestive Therapeutics | 456.72 Mn | 456.72 Mn | 13.47 Mn | -52,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -52,000.00 |
| Mar 31, 2026 | -52,000.00 |
| Dec 31, 2025 | -85,000.00 |
| Dec 31, 2025 | -85,000.00 |
| Sep 30, 2025 | -235,000.00 |
| Sep 30, 2025 | -235,000.00 |
| Jun 30, 2025 | -107,000.00 |
| Jun 30, 2025 | -107,000.00 |
| Mar 31, 2025 | -135,000.00 |
| Mar 31, 2025 | -135,000.00 |
| Dec 31, 2024 | -15,000.00 |
| Dec 31, 2024 | -15,000.00 |
| Sep 30, 2024 | -80,000.00 |
| Sep 30, 2024 | -80,000.00 |
| Jun 30, 2024 | -35,000.00 |
| Jun 30, 2024 | -35,000.00 |
| Mar 31, 2024 | -29,000.00 |
| Mar 31, 2024 | -29,000.00 |
| Dec 31, 2023 | -16,000.00 |
| Dec 31, 2023 | -16,000.00 |